TRIFLURIDINE
Sponsors
Merck Sharp & Dohme LLC, Universitaetsklinikum Heidelberg AöR, Gruppo Oncologico Del Nord Ovest, Association Gercor, National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
Advanced Solid TumorsColorectal CancerHIV InfectionsHerpes SimplexMetastatic Colorectal CancerMetastatic Colorectal cancer (mCRC)Mycobacterium Avium-Intracellulare InfectionStage III and high-risk stage II resected colon cancer patients.
Phase 1
Phase 2
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
TerminatedNCT04854434
Start: 2021-06-29End: 2022-06-24Updated: 2023-11-03
A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory colorectal cancer patients (TROPHIT1)
Active, not recruitingCTIS2023-509771-17-00
Start: 2024-06-04Target: 80Updated: 2025-01-21
Exploiting circulating tumour DNA to intensify the postoperative treatment of stage III and high-risk stage II resected colon cancer patients with adjuvant FOLFOXIRI and/or post-adjuvant Trifluridine/Tipiracil. ERASE-CRC
SuspendedCTIS2024-515152-20-00
Start: 2023-03-02Target: 477Updated: 2024-11-25
BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, multicenter, comparative, randomized GERCOR G-124 BETWEEN phase II study
Not yet recruitingCTIS2024-520128-27-00
Target: 162Updated: 2025-10-20
Phase 3
A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer (KEYFORM-007)
CompletedCTIS2024-511043-25-00
Start: 2021-11-30End: 2025-02-21Target: 102Updated: 2025-02-04
A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
RecruitingCTIS2023-505423-31-00
Start: 2024-08-08Target: 115Updated: 2025-08-20
Unknown Phase
Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine
CompletedNCT00000635
End: 1992-04-30Target: 25Updated: 2021-11-02
Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study
CompletedNCT00002037
Target: 15Updated: 2005-06-24